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Abstract. West Nile virus is a zoonotic agent causing life-threatening encephalitis in a proportion of 
infected patients. Older age, immunosuppression, and mutations in specific host genes (e.g., CCR5 
delta-32 mutation) predispose to neuroinvasive infection. We report on two cases of severe West 
Nile encephalitis in recently-treated, different-aged, chronic lymphocytic leukemia patients. Both 
patients developed high-grade fever associated with severe neurological impairment. The younger 
one harboured germ-line CCR5 delta-32 mutation, which might have played a role in the 
pathogenesis of its neuroinvasive manifestations. 
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Introduction. West Nile virus (WNV) infection is a 
zoonotic disease first recognized in Europe in the 
1960s.1 Although the virus can also be transmitted 
through blood transfusion or organ transplantation, 
humans are mostly infected by Culex mosquitos in the 
transmission season, typically lasting from July to 
October.2 As compared to the previous 4 years, WNV 
infections have sharply increased in Europe in 2018,3 
probably due to circumstances favouring mosquito 
breeding and propagation. While 80% of infected 
patients are asymptomatic, some of them experience 
symptoms ranging from low-grade fever to severe 
neurological illness.2 Several risk factors for central 
nervous system involvement have been identified, 
among which older age,4 impaired adaptive immunity, 
and reduced chemokine receptor 5 (CCR5) expression 
appear pivotal.5 At least the first two conditions are 
frequently shared among patients affected by chronic 
lymphocytic leukemia (CLL), an indolent B-cell 
lymphoproliferative disorder characterized by slowly 
progressive clonal expansion in primary and secondary 
lymphoid organs, and associated with an abnormal T 
helper cell profile.6  
Here we describe two cases of severe WNV 
encephalitis occurring in recently-treated CLL patients 
in August 2018. Both cases have been recorded during 
the infection spike, taking place in Eastern Italy in the 
same period. 
 
Case Report.  
(a) A 53-year-old man was diagnosed with Rai II/Binet 
B CLL in September 2014. Immunoglobulin variable 
region heavy chain genes (IGHV) were unmutated, 
fluorescent in situ hybridization (FISH) for common 
cytogenetic abnormalities was unremarkable and TP53 
status was wild type. Because of massive symptomatic 
splenomegaly, he underwent Rituximab-Fludarabine-
Cyclofosfamide treatment in November 2017 through 
April 2018, achieving partial remission. In August 
2018, he was hospitalized with high-grade fever and 
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fatigue, without rash or meningismus. He denied any 
recent travel, sick contacts, or blood transfusion. 
Despite wide-spectrum antibiotics, his mental status 
and weakness rapidly worsened, also developing 
dizziness and ataxia. White blood cells count was 
4500/μL, with moderate lymphopenia (600/μL). 
Analysis of lymphocyte subpopulation displayed an almost 
total absence of B cells and a reduced number of total T 
(560/μL) and NK cells (16/μL), with marked reduced T 
CD4/CD8 ratio (0.16, normal range 1.15-2.84). There 
was hypogammaglobulinemia (IgG 3.0 g/L) due to 
previous treatments. His cerebrospinal fluid (CSF) was 
clear with normal opening pressure, 
hyperprotidorrachia (65 mg/dL), average glucose, mild 
pleocytosis (10 leukocytes/μL) and negative bacterial 
and fungal cultures. Flow cytometric analysis did not 
show leukemic involvement. Magnetic resonance 
imaging (MRI) returned negative for both focal and 
diffuse signal alterations, whereas 
electroencephalography (EEG) showed diffuse slow 
wave activity without paroxysm. Within 3 days, he 
became poorly responsive to verbal stimuli and 
diffusely hyporeflexic. Because of the clinical suspect 
of viral encephalitis, Acyclovir treatment and 
immunoglobulins supplementation were promptly 
started without improvement in his neurological 
condition. Polymerase chain reaction (PCR) for WNV 
returned positive in both serum and urine, with no 
detectable specific serum antibodies likely due to 
hypogammaglobulinemia. All the other virological 
tests concerning neurotropic viruses, performed on 
CSF and serum, were negative. On hospital day 16, the 
patient’s cognitive performance began to improve, and 
he gradually recovered his motor functions as well as 
osteo-tendon reflexes. Finally, he was discharged and 
transferred to a rehabilitation clinic for a full recovery. 
We searched for anomalies in CCR5. Sequencing of 
Ccr5 gene led to identifying CCR5 delta-32 mutation 
in heterozygosis.  
(b) An 85-year-old woman was diagnosed with Rai 
III/Binet C CLL in June 2014. For progressive and 
symptomatic anemia due to bone marrow failure, the 
patient underwent treatment with Chlorambucil and 
Rituximab in 2016, achieving a temporary 
improvement in her peripheral blood counts. In June 
2018 she experienced a new worsening of anemia with 
high need of transfusion support. FISH and TP53 
mutational status were negative, but cytogenetic 
analysis using B-cell mitogens showed del(3) (p13p21) 
and del(14) (q24) in 8 metaphases out of 20. Because 
of progressive disease, the patient started the second 
line Ibrutinib treatment. However, she autonomously 
discontinued drug assumption due to poor 
gastrointestinal tolerance as soon as thirty days after 
beginning. At the end of July 2018, she was admitted 
to the emergence department with fever, myalgias, 
anorexia and worsening fatigue. Her blood cell counts 
showed moderate lymphocytosis (24000/μL) with mild 
anemia and thrombocytopenia, whereas C-reactive 
protein and procalcitonin were in the normal range. 
Empirical antibiotic therapy was initially administered. 
However, her neurological conditions rapidly worsened 
over the following days, developing psychomotor 
agitation with stereotyped afinalistic movements of the 
lower limbs and altered mental status. Cranial 
computed tomography scan was unremarkable, and 
EEG showed diffuse slowing of background activity 
without focal spikes. Diagnostic lumbar puncture was 
performed, with normal opening pressure, clear CSF, 
pleocytosis of 44 leukocytes/μL (mononuclear 
prevalent), hyperglycorrhachia (66 mmol/L) and 
hyperprotidorrachia (67 mg/dL). As there was the 
clinical suspicion of viral encephalitis, intravenous 
Acyclovir treatment was initially administered. Serum 
and CSF WNV IgM returned positive, whereas all the 
other microbiological tests performed on serum and 
CSF did not. Also, serum WNV PCR was positive. 
Despite supportive measures, the patient’s state of 
consciousness progressively declined, becoming 
unresponsive to any external stimuli. She finally died 
sixteen days after her hospital admission. Sequencing 
of Ccr5 gene revealed no alterations.  
 
Sequencing method. Genomic DNA was extracted from 
200 μL of whole blood by use of QIAamp DNA mini 
kit (Hilden, DE), according to with manufacturer’s 
instructions. DNA was amplified by Platinum Taq 
DNA polymerase High Fidelity (Invitrogen, Carlsbad, 
CA) using primers flanking the site of the 32 base pair 
deletion: 5’-CGCATCAAGTGTCAAGTCCAATC-3’ 
and 5’- TGTAAACTGAGCTTGCTCGCT-3’ (M-
Medical, Cornaredo, IT). PCR products were purified 
with FastGene extraction kit (Nippon Genetics, Tokyo, 
JP). The reverse PCR primer was then used for Sanger 
sequencing with GenomeLab DTCS quick start kit 
(Sciex, Framingham, MA) and CEQ 8000 Genetic 
Analysis System (Sciex) following the manufacturer 
instructions. 
 
Discussion. Since 2008, Italy contribution to European 
WNV infections increased substantially, with peaks of 
cases reported in 2013 and 2015.7 WNV is maintained 
in a continuous mosquito-bird cycle, wherein 
mosquitos are the vectors, and the birds are the 
reservoir. Humans, just like horses and other mammals, 
represent dead-end hosts and do not contribute to 
further spread of the infection.2 West Nile and other 
viral zoonotic infections have long been identified as a 
relevant cause of morbidity in people bearing genetic 
or acquired immune deficiencies. In recent years, the 
rapid spread of WNV infection have been overlapped 
with the rising number of immunocompromised hosts, 
due to increased median life expectancy, more 
powerful anticancer strategies and widespread usage of
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immunosuppressive and immunomodulatory drugs, 
also for autoimmune and other non-malignant 
conditions. In haematological setting, several cases of 
neuroinvasive WNV disease have been reported (Table 
1).8-18 They mainly comprise patients diagnosed with 
WNV encephalitis while on treatment for lymphoid 
malignancies or recently undergone bone marrow 
transplantation, even in paediatric age. Most of them 
were hospitalized due to high-grade fever and 
neurological symptoms ranging from coarse tremor and 
cerebellar ataxia to seizures and confusional state. 
About a half of cases showed thalamic involvement at 
MRI, with hyperintensity on T2-weighted imaging and 
altered FLAIR sequences.8,10-13,15 Diagnosis of 
neuroinvasive disease was confirmed either by positive 
WNV PCR (in CSF or plasma)8,9,10-14,16 or by positive 
serological tests (IgM),12,13,15,18 in the presence of 
suggestive clinical features. Notably, all Rituximab-
treated patients were diagnosed by PCR,8,9,11,14 as 
serological tests always returned negative due to 
treatment-related B-cell impairment. However, 
clinicians may also be aware that viremic phase is short 
in humans,16 thus negative molecular tests do not 
exclude the diagnosis. This makes even more 
challenging the diagnostic process in 
immunocompromised subjects. In them, the outcome 
was fatal for 8 out of 15 patients, and some survivors 
experienced severe neurological sequelae,13,14 which 
often parallel cortical thinning and regional atrophy 
detected by neuroimaging studies.19 None of them was 
evaluated for Ccr5 gene status.  
The two cases we described well recapitulate the 
main clinical and laboratoristic features of severe 
WNV infection. Both of them were affected by CLL 
and were recently treated in an outpatient setting with 
chemoimmunotherapy and Ibrutinib, respectively. To 
our knowledge, only two patients affected by WNV 
encephalitis previously diagnosed with CLL have been 
described in the literature.10,18 Our patients presented 
with fever and went through a rapid deterioration of 
neurological conditions. C-reactive protein was not 
elevated, CSF analysis showed alterations consistent 
with blood-brain barrier (BBB) damage and 
neuroimaging was insignificant. This latter occurs in 
about 50% of patients affected by WNV encephalitis, 
the other half developing abnormal MRI findings, 
which commonly involve thalami, basal ganglia, 
mesial temporal structures, brain stem, and 
cerebellum.20 In the first, Rituximab-treated, patient, 
the diagnosis was based on positive WNV PCR, as 
serology returned negative. The fatal outcome of the 
second patient was likely favoured by older age and 
female gender, usually associated with worse recovery 
from coma.21    
Since most neuroinvasive WNV disease in non-
haematological setting occur in the elderly,2 the 
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development of such a severe clinical picture in the 
first, young patient prompted us to investigate the 
presence of Ccr5 delta-32 mutation as an additional 
risk factor for neuroinvasive infection.22 CCR5 is the G 
protein-coupled receptor binding to three CC 
chemokines, namely CCL3, CCL4 and CCL5, involved 
in T lymphocyte trafficking through the BBB. It is 
mainly expressed by T helper 1 subset upon antigen 
recognition, whereby coupling the amplification of the 
inflammatory response with the appropriate 
environmental context.23,24 By sequencing the Ccr5 
gene, we found the patient was heterozygous for the 
delta-32 mutation, which generates a truncated form of 
CCR5 persistently retained within the endoplasmic 
reticulum, thus lowering its surface expression. Of 
note, delta-32 CCR5 has been reported to act as a 
dominant negative mutant, further reducing the cell 
sensing for CCR5 cognate ligands.25 Therefore, 
impairment of CCR5-based chemotactic system, along 
with low T CD4 cell count due to previous 
chemotherapy, may have played a non-negligible role 
in the pathogenesis of his neuroinvasive WNV 
infection. We speculate that Ccr5 genotyping might be 
of some importance to identify immunocompromised 
patients particularly at risk for life-threatening 
neurological complications. Effective preventive 
strategies, mostly still to be uncovered, might be 
primarily directed to them. 
 
Conclusions. The two cases we reported highlight 
some general considerations. First, the rapid spread of 
WNV infection should induce clinicians to take it into 
account within the diagnostic workup of 
immunocompromised patients with fever and 
neurological symptoms, especially in summer months. 
In haematological setting, outpatient regimens are even 
likely to increase the risk of neuroinvasive disease, and 
diagnosis may be difficult in those patients treated with 
monoclonal antibodies blunting humoral response. 
Then, assessment of genetic risk factors for severe 
WNV infection, such as Ccr5 delta-32 mutation, may 
be useful to direct future preventive or pre-emptive 
strategies. However, supportive measures remain the 
only way to face the disease so far, and fatal outcome 
is still frequent.  
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